rss
Br J Ophthalmol 2009;93:1005-1015 doi:10.1136/bjo.2008.151266
  • Original Article
  • Clinical science

Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial

  1. U C Christensen,
  2. K Krøyer,
  3. B Sander,
  4. M Larsen,
  5. V Henning,
  6. J Villumsen,
  7. M la Cour
  1. Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark
  1. Correspondence to Dr U C Christensen, Department of Ophthalmology, Glostrup Hospital, Nordre Ringvej 57, DK-2600 Glostrup, Denmark; ulrikchristensen{at}dadlnet.dk
  • Accepted 17 October 2008
  • Published Online First 21 November 2008

Abstract

Aim: To determine the effect of internal limiting membrane (ILM) peeling on anatomical and functional success rates in stage 2 and 3 idiopathic macular hole surgery (MHS).

Methods: Randomised clinical trial of stage 2 and 3 idiopathic macular hole without visible epiretinal fibrosis and with less than 1 year’s duration of symptoms. Eyes were randomised to (1) vitrectomy alone without retinal surface manipulation, (2) vitrectomy plus 0.05% isotonic Indocyanine Green (ICG)-assisted ILM peeling or (3) vitrectomy plus 0.15% Trypan Blue (TB)-assisted ILM peeling. Main outcomes were hole closure after 3 and 12 months and best-corrected visual acuity after 12 months.

Results: 78 eyes were enrolled. Primary closure rates were significantly higher with ILM peeling than without peeling for both stage 2 holes (ICG peeling 100%, non-peeling 55%, p = 0.014) and for stage 3 holes (ICG peeling 91%, TB peeling 89%, non-peeling 36%, p<0.001). Visual outcomes in eyes with primary hole closure were not significantly different between the groups.

Conclusions: Dye-assisted ILM peeling was associated with significantly higher closure rates than non-peeling in both stage 2 and 3 MHS. Intraoperative ILM staining with 0.05% isotonic ICG was not associated with a significantly different visual outcome than non-peeling or TB peeling in eyes with primary hole closure.

Trial registration number: NCT00302328.

Footnotes

  • Funding The Danish Eye Health Society, The Danish Medical Research Council, The John and Birthe Meyer Foundation and The Velux Foundation.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Danish Committee for Biomedical Research Ethics.

  • Patient consent Obtained.

  • See Editorial, p 987

Relevant Article

  • At a glance: At a glance Br J Ophthalmol 2009;93:i doi:10.1136/bjo.2009.167163

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjo.2008.151266v1
    2. 93/8/1005 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.